國際頂級學術期刊JCO權威發表翰森製藥肺癌創新藥阿美樂最新研究成果
格隆匯5月19日丨國際著名腫瘤學期刊《臨牀腫瘤學雜誌》(JCO,IF:44.544)18日在線發表了翰森製藥(3692.HK)創新藥阿美樂(甲磺酸阿美替尼片)最新研究成果。這是ASCO官方期刊首次發表中國原創三代EGFR-TKI臨牀數據。 該研究由上海交通大學附屬胸科醫院陸舜教授主持,是一項多中心隨機雙盲對照的Ⅲ期研究,關於阿美替尼對比吉非替尼作為一線針對EGFR敏感突變陽性局部晚期或轉移性非小細胞肺癌患者的治療,總計超過400例受試者參加。研究結果顯示,與現有的一線標準治療藥物吉非替尼相比,使用阿美替尼一線治療的患者,無進展生存期、持續緩解時間均顯著延長,並可為腦轉移患者帶來更多獲益,在安全性和有效性方面均具有卓越優勢。此項研究入組患者全部為中國患者,是首個三代 EGFR-TKI 藥物針對中國肺癌患者一線治療的隨機對照研究,證據等級更高,更能反映中國肺癌患者的疾病狀況。此前,該研究於2021年ASCO年會首次公佈研究進展,獲得國際同行廣泛關注。2022年ASCO年會將進一步發佈其腦轉移亞組數據的最新進展。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.